China Securities Journal (Wang Luo) – Recently, information released by the National Medical Products Administration (NMPA) shows that Dongyangguang Pharmaceutical 's independently developed Class 1 new drug, small interfering RNA (siRNA) HECN30227 injection, has been approved for clinical research in the treatment of chronic hepatitis B. This is another significant advancement in nucleic acid drug development in China's biopharmaceutical field, marking a significant step forward for domestic companies in innovative drug development.The development of the track continues to accelerate.

　　In recent years, guided by policies and driven by the market, China's biopharmaceutical industry has gradually built a complete ecosystem covering basic research, clinical translation, and industrialization. HECN30227, which has now been approved, is a product of Dongyangguang Pharmaceutical based on its independent intellectual property rights.The development of the innovative small interfering RNA (siRNA) drug demonstrates China's research strength and technological accumulation in the field of nucleic acid drugs. This drug participates in the regulation of the hepatitis B virus life cycle through a specific mechanism, providing a research sample for exploring novel treatment pathways. Based on this, Dongyangguang Pharmaceutical is simultaneously developing a triple therapy combining siRNA, ASO, and an immunomodulator.

　　It is understood that a significant research finding on the preclinical combination of HECN30227 and the company's self-developed highly selective hTLR8 immune agonist has recently been selected as a "Poster of Distinction" at the 2025 American Association for the Study of Liver Diseases (AASLD) Annual Meeting. This title is awarded only to results ranking in the top 10% of the score, signifying the high recognition of HECN30227's clinical development potential by international authoritative academic institutions.

　　Public information shows that DongyangguangIn recent years, the company has continuously increased its R&D investment, building a full-chain R&D platform encompassing "target discovery – sequence design – chemical modification – delivery technology – biological evaluation." The approval of HECN30227 is a significant milestone in the transformation and application of this technology platform. Based on this comprehensive platform, the company has developed over 10 small nucleic acid drugs, covering four major areas: anti-infectives, cardiovascular-renal-metabolic drugs, and respiratory and oncology. It plans to advance multiple small nucleic acid drugs into clinical trials annually, continuously consolidating its leading technological advantage in this field.

　　According to reports, nucleic acid drugs are becoming a hot area of ​​global new drug research and development due to their unique targeting and long-lasting effects.

　　A representative from Dongyangguang Pharmaceutical stated that in the future, Dongyangguang Pharmaceutical will continue to increase investment in the construction of technology platforms such as small molecules, small nucleic acids, ADCs, and PROTACs to accelerate the overcoming of unmet clinical needs and bring patients globally leading "Made in China" treatment solutions.

https://finance.eastmoney.com/a/202510303549934886.html